Related Experiment Video
Updated: Apr 15, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma
Christopher A Yasenchak1,2, Wan-Yu Tseng2, Mark Yap2
1a Willamette Valley Cancer Institute/The US Oncology Network, McKesson Specialty Health , Springfield , OR , USA.
Insights
Treating progressive Hodgkin lymphoma (HL) incurs substantial costs, especially with stem cell transplants. Early intervention to prevent relapse could significantly reduce the economic burden of HL treatment.
Area of Science:
- Oncology
- Health Economics
- Clinical Research
Background:
- Hodgkin lymphoma (HL) management involves multiple treatment lines.
- Progressive disease significantly impacts patient care and healthcare costs.
- Understanding the economic burden is crucial for resource allocation.
Purpose of the Study:
- To evaluate the economic burden of progressive Hodgkin lymphoma (HL).
- To analyze costs associated with second- and third-line therapies for HL.
- To identify cost-saving opportunities in HL treatment strategies.
Main Methods:
- Retrospective, observational cohort study.
- Analysis of electronic health records from a US community practice network.
- Inclusion of adult patients with classical HL receiving chemotherapy (2007-2011).
Main Results:
- Mean costs per line of therapy: LOT1 ($21,956), LOT2 ($77,219), LOT3 ($59,442).
- Transplant in LOT2 and LOT3 increased costs 7-8 fold compared to LOT1.
- Costs were approximately $154,000 (LOT2) and $193,000 (LOT3) with transplant.
Conclusions:
- Progressive Hodgkin lymphoma (HL) presents a significant economic burden.
- The cost of care escalates substantially with each subsequent line of therapy, particularly with transplants.
- Early intervention strategies to prevent or delay relapse are likely to yield considerable cost savings.
Abstract:
The current study aimed to assess the economic burden of progressive disease among patients with Hodgkin lymphoma (HL) receiving second- or third-line therapy in a large US network of community-based practices. This retrospective, observational cohort analysis used electronic health records to examine adult patients with classical HL who received chemotherapy between 2007 and 2011. Of 291 observations, 112 had non-progressive disease (received only one line of therapy; LOT1), 114 received second-line therapy (LOT2), and 65 received third-line therapy (LOT3). In LOT2, 49 patients (43%) underwent transplant. In LOT3, 13 patients (20%) underwent transplant. The mean total cost per line of therapy was $21 956 in LOT1, $77 219 in LOT2, and $59 442 in LOT3. When transplant was required, the mean total cost per line of therapy increased 7- to 8-fold when compared with the cost of LOT1 (approximately $154 000 for LOT2 and $193 000 for LOT3). Future therapies that intervene as early as possible in the treatment algorithm to prevent or significantly delay relapse will likely result in significant cost savings.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
01:21Cancer Survival Analysis
01:17Classification of Illness
An illness is a response to a disease in which the person's level of functioning is changed compared with a previous level. The general classification of illness includes acute and chronic.
Acute illness is severe...